GP IIb/IIIa inhibitors during primary percutaneous coronary intervention for STEMI: New trial and registry data

被引：2

作者：

Tamhane U.U. ^{[1
]}

Gurm H.S. ^{[2
]}

机构：

[1] Department of Medicine, Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI

[2] VA Ann Arbor Health Care System, University of Michigan Cardiovascular Center, Ann Arbor, MI 48109-5853, 2A394

来源：

Current Cardiology Reports | 2008年 / 10卷 / 5期

关键词：

Percutaneous Coronary Intervention; Abciximab; Major Adverse Cardiac Event; Primary Percutaneous Coronary Intervention; Target Lesion Revascularization;

D O I：

10.1007/s11886-008-0066-5

中图分类号：

学科分类号：

摘要：

Primary percutaneous coronary intervention (PCI) with adjunctive glycoprotein (GP) IIb/IIIa receptor inhibitor therapy administered in the cardiac catheterization laboratory is the optimal reperfusion strategy for patients with ST-elevation myocardial infarction. Most available data regarding these agents are from trials comparing abciximab to placebo alone. Noninferiority trials comparing small-molecule GP IIb/IIIa receptor inhibitors, such as tirofiban and eptifibatide with abciximab, have used markers for myocardial reperfusion as primary end points but are underpowered to detect significant differences in hard clinical outcomes. Such a trial would need to enroll a very large number of patients and thus make it practically impossible to perform. Registry data reveal that most patients undergoing primary PCI are treated with small-molecule GP IIb/ IIIa receptor inhibitors in clinical practice, and no observed difference is observed in safety and efficacy when compared with patients treated with abciximab therapy. © Current Medicine Group LLC 2008.

引用

页码：424 / 430

页数：6

共 24 条

[1]

Antman E.M., Anbe D.T., Armstrong P.W., Et al., ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction, Circulation, 110, (2004)

[2]

Gawaz M., Neumann F.J., Ott I., Et al., Platelet function in acute myocardial infarction treated with direct angioplasty, Circulation, 93, pp. 229-237, (1996)

[3]

Smith S.C., Feldman T.E., Hirshfeld J.W., Et al., ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention - Summary article: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention), Circulation, 113, pp. 156-175, (2006)

[4]

Bhatt D.L., Topol E.J., Current role of platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes, JAMA, 284, pp. 1549-1558, (2000)

[5]

Schror K., Weber A.A., Comparative pharmacology of GP IIb/IIIa antagonists, J Thromb Thrombolysis, 15, pp. 71-80, (2003)

[6]

Brener S.J., Barr L.A., Burchenal J.E., Et al., Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators, Circulation, 98, pp. 734-741, (1998)

[7]

Montalescot G., Barragan P., Wittenberg O., Et al., Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction, N Engl J Med, 344, pp. 1895-1903, (2001)

[8]

Neumann F.J., Kastrati A., Schmitt C., Et al., Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction, J Am Coll Cardiol, 35, pp. 915-921, (2000)

[9]

Stone G.W., Grines C.L., Cox D.A., Et al., Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction, N Engl J Med, 346, pp. 957-966, (2002)

[10]

Topol E.J., Neumann F.J., Montalescot G., A preferred reperfusion strategy for acute myocardial infarction, J Am Coll Cardiol, 42, pp. 1886-1889, (2003)

← 1 2 3 →